185 related articles for article (PubMed ID: 28299358)
1. A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma.
Hsiao SJ; Karajannis MA; Diolaiti D; Mansukhani MM; Bender JG; Kung AL; Garvin JH
Cold Spring Harb Mol Case Stud; 2017 Mar; 3(2):a001396. PubMed ID: 28299358
[TBL] [Abstract][Full Text] [Related]
2. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.
Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C
Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325
[TBL] [Abstract][Full Text] [Related]
3. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.
Dias-Santagata D; Lam Q; Vernovsky K; Vena N; Lennerz JK; Borger DR; Batchelor TT; Ligon KL; Iafrate AJ; Ligon AH; Louis DN; Santagata S
PLoS One; 2011 Mar; 6(3):e17948. PubMed ID: 21479234
[TBL] [Abstract][Full Text] [Related]
4. The genetic landscape of anaplastic pleomorphic xanthoastrocytoma.
Phillips JJ; Gong H; Chen K; Joseph NM; van Ziffle J; Bastian BC; Grenert JP; Kline CN; Mueller S; Banerjee A; Nicolaides T; Gupta N; Berger MS; Lee HS; Pekmezci M; Tihan T; Bollen AW; Perry A; Shieh JTC; Solomon DA
Brain Pathol; 2019 Jan; 29(1):85-96. PubMed ID: 30051528
[TBL] [Abstract][Full Text] [Related]
5. BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression.
Koelsche C; Sahm F; Wöhrer A; Jeibmann A; Schittenhelm J; Kohlhof P; Preusser M; Romeike B; Dohmen-Scheufler H; Hartmann C; Mittelbronn M; Becker A; von Deimling A; Capper D
Brain Pathol; 2014 Apr; 24(3):221-9. PubMed ID: 24345274
[TBL] [Abstract][Full Text] [Related]
6. Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship.
Lin Z; Yang R; Zheng H; Li Z; Yi G; Wu Q; Yang C; Huang G
Clin Neurol Neurosurg; 2022 Oct; 221():107379. PubMed ID: 35932588
[TBL] [Abstract][Full Text] [Related]
7. Establishment and characterization of patient-derived xenograft of a rare pediatric anaplastic pleomorphic xanthoastrocytoma (PXA) bearing a CDC42SE2-BRAF fusion.
Damayanti NP; Saadatzadeh MR; Dobrota E; Ordaz JD; Bailey BJ; Pandya PH; Bijangi-Vishehsaraei K; Shannon HE; Alfonso A; Coy K; Trowbridge M; Sinn AL; Zhang ZY; Gallagher RI; Wulfkuhle J; Petricoin E; Richardson AM; Marshall MS; Lion A; Ferguson MJ; Balsara KE; Pollok KE
Sci Rep; 2023 Jun; 13(1):9163. PubMed ID: 37280243
[TBL] [Abstract][Full Text] [Related]
8. BRAF V600E, TERT, and IDH2 Mutations in Pleomorphic Xanthoastrocytoma: Observations from a Large Case-Series Study.
Ma C; Feng R; Chen H; Hameed NUF; Aibaidula A; Song Y; Wu J
World Neurosurg; 2018 Dec; 120():e1225-e1233. PubMed ID: 30240866
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
[TBL] [Abstract][Full Text] [Related]
10. BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma.
Tabouret E; Bequet C; Denicolaï E; Barrié M; Nanni I; Metellus P; Dufour H; Chinot O; Figarella-Branger D
Eur J Surg Oncol; 2015 Dec; 41(12):1685-90. PubMed ID: 26454767
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological characteristics of circumscribed high-grade astrocytomas with an unusual combination of BRAF V600E, ATRX, and CDKN2A/B alternations.
Murakami C; Yoshida Y; Yamazaki T; Yamazaki A; Nakata S; Hokama Y; Ishiuchi S; Akimoto J; Shishido-Hara Y; Yoshimoto Y; Matsumura N; Nobusawa S; Ikota H; Yokoo H
Brain Tumor Pathol; 2019 Jul; 36(3):103-111. PubMed ID: 30972500
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma.
Ida CM; Vrana JA; Rodriguez FJ; Jentoft ME; Caron AA; Jenkins SM; Giannini C
Acta Neuropathol Commun; 2013 May; 1():20. PubMed ID: 24252190
[TBL] [Abstract][Full Text] [Related]
13. BRAF/MEK Dual Inhibitors Therapy in Progressive and Anaplastic Pleomorphic Xanthoastrocytoma: Case Series and Literature Review.
Kata K; Rodriguez-Quintero JC; Arevalo OD; Zhang JJ; Bhattacharjee MB; Ware C; Dono A; Riascos-Castaneda R; Tandon N; Blanco A; Esquenazi Y; Ballester LY; Amsbaugh M; Day AL; Zhu JJ
J Natl Compr Canc Netw; 2022 Nov; 20(11):1193-1202.e6. PubMed ID: 36351333
[TBL] [Abstract][Full Text] [Related]
14. Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations.
Yamada S; Kipp BR; Voss JS; Giannini C; Raghunathan A
Am J Surg Pathol; 2016 Feb; 40(2):279-84. PubMed ID: 26414224
[TBL] [Abstract][Full Text] [Related]
15. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series.
Chamberlain MC
J Neurooncol; 2013 Sep; 114(2):237-40. PubMed ID: 23756728
[TBL] [Abstract][Full Text] [Related]
16. Molecular features of pleomorphic xanthoastrocytoma.
Zou H; Duan Y; Wei D; Zhang Y; Dai J; Li J; Li X; Zhou J; Liu Z; Jin Z; Zhang Z; Yu Y; Hu Z
Hum Pathol; 2019 Apr; 86():38-48. PubMed ID: 30496796
[TBL] [Abstract][Full Text] [Related]
17. Combined pleomorphic xanthoastrocytoma-ganglioglioma with BRAF V600E mutation: case report.
Cicuendez M; Martinez-Saez E; Martinez-Ricarte F; Asanza EC; Sahuquillo J
J Neurosurg Pediatr; 2016 Jul; 18(1):53-7. PubMed ID: 27015517
[TBL] [Abstract][Full Text] [Related]
18. Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation.
Tanaka S; Nakada M; Nobusawa S; Suzuki SO; Sabit H; Miyashita K; Hayashi Y
Brain Tumor Pathol; 2014 Jul; 31(3):172-6. PubMed ID: 24894018
[TBL] [Abstract][Full Text] [Related]
19. Clinical, Morphological, and Molecular Study on Grade 2 and 3 Pleomorphic Xanthoastrocytoma.
Zhang H; Ma XJ; Xiang XP; Wang QY; Tang JL; Yu XY; Xu JH
Curr Oncol; 2023 Feb; 30(2):2405-2416. PubMed ID: 36826144
[TBL] [Abstract][Full Text] [Related]
20. BRAF V600E-mutated central nervous system tumor with divergent morphological feature - Anaplastic pleomorphic xanthoastrocytoma-like and astroblastoma-like.
Purkait S; Bansal S; Malgulwar PB
Neuropathology; 2019 Feb; 39(1):64-67. PubMed ID: 30557911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
